StockpollyBeta
Get App
Popularity #2,132Earnings today
RZLT · NASDAQ · Biotechnology

Rezolute (RZLT)

Developing ersodetug for hypoglycemia caused by congenital and tumor hyperinsulinism.

$4.01
After hours−0.03 (−0.74%)
At close$4.04(+3.32%)

In millions of USD, except per-share figures

In millionsQ4 FY23Jun 2023Q1 FY24Sep 2023Q2 FY24Dec 2023Q3 FY24Mar 2024Q4 FY24Jun 2024Q1 FY25Sep 2024Q2 FY25Dec 2024Q3 FY25Mar 2025Q4 FY25Jun 2025Q1 FY26Sep 2025Q2 FY26Dec 2025Q3 FY26Mar 2026
Cost of revenue000000000000
Gross profit000000000000
141615162317172026202417
Research & development111212121913131521131411
3434444557106
Selling & marketing000000000000
General & administrative3434444557106
Other expenses000000000000
Operating income−14−16−15−16−23−17−17−20−26−20−24−17
211−102111211
Interest income111112111211
Other non-operating income−2−1−110−2−1−1−1−2−1−1
Income before tax−13−15−14−17−23−15−16−19−24−18−23−16
Net income from continuing operations−13−15−14−17−23−15−16−19−24−18−23−16
Net income−13−15−14−17−23−15−16−19−24−18−23−16
EPS, basic−$0.25−$0.28−$0.27−$0.34−$0.45−$0.22−$0.22−$0.27−$0.26−$0.18−$0.22−$0.16
EPS, diluted−$0.25−$0.28−$0.27−$0.34−$0.45−$0.22−$0.22−$0.27−$0.26−$0.18−$0.22−$0.16
Weighted average shares, basic515151515170707094103104104
Weighted average shares, diluted515151515170707094103104104
EBITDA−13−15−14−17−23−15−16−19−24−18−23−16
Depreciation & amortization000000000000
EBIT−13−15−14−17−23−15−16−19−24−18−23−16